David Dai
Stock Analyst at UBS
(4.31)
# 1,356
Out of 4,655 analysts
100
Total ratings
62.7%
Success rate
16.2%
Average return
Main Sectors:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SMMT Summit Therapeutics | Maintained: Buy | $33 | $12.78 | +158.22% | 8 | Aug 18, 2026 | |
| CGEM Cullinan Therapeutics | Maintained: Buy | $24 → $27 | $20.59 | +31.13% | 8 | Aug 17, 2026 | |
| KYMR Kymera Therapeutics | Maintained: Buy | $128 | $121.41 | +5.43% | 3 | Aug 5, 2026 | |
| BNTX BioNTech SE | Maintained: Buy | $135 | $91.60 | +47.38% | 2 | Aug 4, 2026 | |
| NRIX Nurix Therapeutics | Rated: Buy | $23 → $31 | $27.17 | +14.10% | 6 | Jul 22, 2026 | |
| ASX: TLX Telix Pharmaceuticals Limited | Maintained: Buy | $31.00 | $16.79 | +84.63% | 14 | Jul 1, 2026 | |
| CLDX Celldex Therapeutics | Maintained: Buy | $45 | $41.92 | +7.35% | 2 | Jun 16, 2026 | |
| NBTX Nanobiotix | Maintained: Hold | $30 | $42.05 | -28.66% | 5 | Jun 4, 2026 | |
| KURA Kura Oncology | Maintained: Buy | $15 | $11.28 | +32.98% | 7 | Jun 3, 2026 | |
| ENGN enGene Therapeutics | Maintained: Hold | $9 → $2 | $1.70 | +17.65% | 4 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $38 → $37 | $19.76 | +87.25% | 4 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $90 | $77.11 | +16.72% | 4 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $69 → $15 | $16.26 | -7.75% | 2 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1.5 | $0.8422 | +78.10% | 2 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $7 → $8 | $3.22 | +148.45% | 3 | Mar 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $2 → $4 | $7.10 | -43.66% | 3 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $40 → $34 | $64.46 | -47.25% | 3 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $546 | $515.55 | +5.91% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $112 | $138.92 | -19.38% | 1 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $50 | $36.54 | +36.84% | 3 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | ¥2,690 | ¥8,734 | n/a | 6 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | ¥34,600 | ¥57,210 | n/a | 1 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | ¥3,900 | ¥3,743 | n/a | 1 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $5 | $7.15 | n/a | 1 | Sep 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $40 → $5 | $4.06 | n/a | 2 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $40 | $2.43 | n/a | 1 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $54 | $23.12 | n/a | 2 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $28 | $8.74 | n/a | 1 | Mar 30, 2022 |
Summit Therapeutics
Aug 18, 2026
Maintained: Buy
Price Target: $33
Current: $12.78
Upside: +158.22%
Cullinan Therapeutics
Aug 17, 2026
Maintained: Buy
Price Target: $24 → $27
Current: $20.59
Upside: +31.13%
Kymera Therapeutics
Aug 5, 2026
Maintained: Buy
Price Target: $128
Current: $121.41
Upside: +5.43%
BioNTech SE
Aug 4, 2026
Maintained: Buy
Price Target: $135
Current: $91.60
Upside: +47.38%
Nurix Therapeutics
Jul 22, 2026
Rated: Buy
Price Target: $23 → $31
Current: $27.17
Upside: +14.10%
Telix Pharmaceuticals Limited
Jul 1, 2026
Maintained: Buy
Price Target: $31.00
Current: $16.79
Upside: +84.63%
Celldex Therapeutics
Jun 16, 2026
Maintained: Buy
Price Target: $45
Current: $41.92
Upside: +7.35%
Nanobiotix
Jun 4, 2026
Maintained: Hold
Price Target: $30
Current: $42.05
Upside: -28.66%
Kura Oncology
Jun 3, 2026
Maintained: Buy
Price Target: $15
Current: $11.28
Upside: +32.98%
enGene Therapeutics
May 14, 2026
Maintained: Hold
Price Target: $9 → $2
Current: $1.70
Upside: +17.65%
May 13, 2026
Maintained: Buy
Price Target: $38 → $37
Current: $19.76
Upside: +87.25%
May 8, 2026
Maintained: Buy
Price Target: $90
Current: $77.11
Upside: +16.72%
Apr 15, 2026
Downgraded: Hold
Price Target: $69 → $15
Current: $16.26
Upside: -7.75%
Apr 2, 2026
Maintained: Hold
Price Target: $1.5
Current: $0.8422
Upside: +78.10%
Mar 18, 2026
Rated: Buy
Price Target: $7 → $8
Current: $3.22
Upside: +148.45%
Mar 5, 2026
Rated: Hold
Price Target: $2 → $4
Current: $7.10
Upside: -43.66%
Jan 7, 2026
Downgraded: Hold
Price Target: $40 → $34
Current: $64.46
Upside: -47.25%
Nov 7, 2025
Maintained: Buy
Price Target: $546
Current: $515.55
Upside: +5.91%
Oct 31, 2025
Reiterated: Hold
Price Target: $112
Current: $138.92
Upside: -19.38%
Oct 24, 2025
Maintained: Buy
Price Target: $50
Current: $36.54
Upside: +36.84%
Apr 2, 2025
Maintained: Hold
Price Target: ¥2,690
Current: ¥8,734
Upside: n/a
Feb 26, 2025
Reiterated: Buy
Price Target: ¥34,600
Current: ¥57,210
Upside: n/a
Jan 15, 2025
Initiated Coverage: Buy
Price Target: ¥3,900
Current: ¥3,743
Upside: n/a
Sep 29, 2022
Initiated Coverage: Buy
Price Target: $5
Current: $7.15
Upside: n/a
Jul 18, 2022
Downgraded: Hold
Price Target: $40 → $5
Current: $4.06
Upside: n/a
May 16, 2022
Maintained: Buy
Price Target: $40
Current: $2.43
Upside: n/a
May 9, 2022
Maintained: Buy
Price Target: $54
Current: $23.12
Upside: n/a
Mar 30, 2022
Initiated Coverage: Buy
Price Target: $28
Current: $8.74
Upside: n/a